Specialty Pharmacy

As health care costs continue to increase, and with high-cost specialty products making up a significant portion of the pipeline, the role of the Specialty Pharmacy (SP) continues to grow and influence health care decisions across multiple stakeholders.

The FDA released a statement on February 14, 2012, warning pharmacies, medical practices, and patients that a counterfeit version of the drug Avastin-an injectable drug used to treat cancer of the colon, lung, kidney, and brain-has been purchased and used by some medical practices in the United States.

The Centers for Disease Control and Prevention (CDC) recently added to their list of HIV resources in the Electronic HIV/AIDS Prevention (e-Hap) portion of their website, a section which is produced with content from CDC's Division of HIV/AIDS prevention (DHAP).

The U.S. Food and Drug Administration today issued three draft guidance documents on biosimilar product development to assist industry in developing such products in the United States.

The FDA sent out a "Drug Safety Communication" from their Division of Drug Information on February 9, 2012, listing the important new drug interactions between Victrelis (boceprevir) and ritonavir-boosted HIV protease inhibitor drugs.

Show your support for World Cancer Day on February 4, 2012, by pledging to make healthier choices through the use of social media applications dedicated to the cause.

Acquisition strengthens Walgreens retail specialty pharmacy offering with access to additional drug therapies and services.

Today, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer.

The FDA points out the risk factors associated with using unapproved cancer injectables and issues new warnings to health care providers.

Serving a growing market, the new Specialty Pharmacy Times Website provides industry news, current clinical insights, and specialty trends and practices.

New rules will require physicians to report their financial transactions with drug companies through a public database.

Florida's new pain management law sparks a discussion about restricting access to controlled substances.

Manufactures are faced with multiple challenges as the FDA imposes far-reaching requirements for their production.

What you need to know about the latest draft guidance for manufactures regarding medication guides and the current scene of classwide REMs.

Opposition to the Express Scripts-Medco merger stems from concerns over reduced access, increased prices, and diminished patient care.

Pharmacy Times publishes the third edition of this new journal with a special focus on oncology trends for the growing specialty pharmacy market.

What pharmacists need to know now about this standardization and how it affects the industry.

What each stakeholder needs to know about REMS in today's fast-paced climate.